74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Coherus Oncology Inc
Open
SectorHealthcare
1.98 0.51
Overview
Share price change
24h
Min
1.92
Max
1.98
Income | 277M 241M |
|---|---|
Sales | 1.2M 13M |
P/E Sector Avg | 3.509 63.808 |
Profit margin | 1,892.046 |
Employees | 147 |
EBITDA | -2M -43M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +253.54% upside |
Next Earnings | 11 May 2026 |
|---|
Market Cap | 9.7M 256M |
|---|---|
Previous open | 1.47 |
Previous close | 1.98 |
News Sentiment
By Acuity
50%
50%
135 / 348 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Coherus Oncology Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Coherus Oncology Inc Forecast
Price Target
By TipRanks
253.54% upside
12 Months Forecast
Average 7 USD 253.54%
High 10 USD
Low 4 USD
Based on 4 Wall Street analysts offering 12 month price targets forCoherus Oncology Inc - Dist in the last 3 months.
Sentiment
By Acuity
135 / 348 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Coherus Oncology Inc
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Live chat